Bullish Reversal Built-Up
Updated
Sanofi shares have been plummeting because of lowering net income, disappointing return on equity and performance in the stock itself.
However, market was overreacting and short-term bullish reversal ought to be considered.
However, market was overreacting and short-term bullish reversal ought to be considered.
Note
No development for this stock, bottom appears to be built but there might be no rise in the share price unless market triggers a clear bullish impulse upwards. And the market is now choppy … I’ll be waiting for some good company news that may persuade people to invest in this stock.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.